FIELD: medicine.
SUBSTANCE: invention relates to crystalline form A of the compound of formula I, where its powder x-ray diffraction pattern contains diffraction peaks at 2Θ5.95°, 10.10°, 15.14°, 18.83°, 20.23° where error range 2Θ is ±0.2°, as well as to a method of its preparation and use for the treatment or prevention of a disease associated with the farnesoid X receptor.
EFFECT: obtaining a crystalline form of a new compound which is stable, pure and non-hygroscopic, and can be used in medicine for the treatment of diseases associated with the farnesoid X receptor (FXR), for example, such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis (PBC), cholestatic hepatopathy, chronic liver disease, obesity, type 2 diabetes, etc.
7 cl, 12 dwg, 5 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE FORMS OF THE TLR7/TLR8 INHIBITOR | 2019 |
|
RU2792005C2 |
| AMORPHOUS DERIVATIVE OF PYRROLIDINE AS PPAR AGONIST AND METHOD FOR PRODUCTION THEREOF | 2018 |
|
RU2749056C1 |
| COMPOUND OF BRD4 INHIBITOR IN SOLID FORM, METHOD FOR ITS PRODUCTION AND APPLICATION | 2020 |
|
RU2793346C1 |
| CRYSTAL FORM OF PHOSPHODIESTERASE INHIBITOR, METHOD OF ITS PREPARATION AND USE | 2020 |
|
RU2814498C2 |
| CRYSTALLINE FORM OF SMAC MIMETIC USED AS IAP INHIBITOR, AND METHOD FOR PRODUCTION THEREOF | 2020 |
|
RU2819398C2 |
| SALTS AND POLYMORPHS OF SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE | 2015 |
|
RU2732125C2 |
| SOLID FORM, CRYSTALLINE, AND CRYSTALLINE A OF FXR AGONIST AND METHOD FOR THEIR PRODUCTION AND THEIR APPLICATION | 2019 |
|
RU2804320C2 |
| PYRIDO[1,2-A]PYRIMIDONE ANALOG, ITS CRYSTAL FORM, ITS INTERMEDIATE COMPOUND AND METHOD FOR THEIR PREPARATION | 2016 |
|
RU2753696C2 |
| CRYSTALLINE FORM AND METHOD OF CLEANING SAME | 2011 |
|
RU2604734C2 |
| SYK INHIBITOR SALT AND CRYSTALLINE FORM THEREOF | 2019 |
|
RU2818103C2 |
